Element Capital Management LLC Makes New $1.62 Million Investment in Lumexa Imaging Holdings, Inc. $LMRI

Element Capital Management LLC purchased a new stake in Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 87,352 shares of the company’s stock, valued at approximately $1,616,000. Lumexa Imaging accounts for about 0.8% of Element Capital Management LLC’s portfolio, making the stock its 29th largest position. Element Capital Management LLC owned about 0.09% of Lumexa Imaging as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Assetmark Inc. purchased a new stake in Lumexa Imaging in the fourth quarter valued at approximately $36,000. Barclays PLC acquired a new stake in shares of Lumexa Imaging in the fourth quarter valued at $133,000. Sandia Investment Management LP purchased a new stake in shares of Lumexa Imaging in the 4th quarter valued at $185,000. Hudson Bay Capital Management LP acquired a new position in Lumexa Imaging during the 4th quarter worth about $237,000. Finally, Burkehill Global Management LP purchased a new position in Lumexa Imaging during the 4th quarter valued at about $925,000.

Insiders Place Their Bets

In other news, Director Brett Brodnax purchased 35,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average price of $7.25 per share, for a total transaction of $253,750.00. Following the completion of the purchase, the director directly owned 62,027 shares of the company’s stock, valued at $449,695.75. The trade was a 129.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on LMRI. Weiss Ratings raised shares of Lumexa Imaging from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, June 1st. Barclays cut their target price on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Lumexa Imaging Trading Down 2.7%

LMRI stock opened at $8.79 on Thursday. The firm has a 50-day moving average of $8.84. Lumexa Imaging Holdings, Inc. has a 1 year low of $6.45 and a 1 year high of $19.45.

Lumexa Imaging Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).